Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

被引：165

作者：

Asghar, Uzma ^{[2
]}

Meyer, Tim ^{[1
,2
]}

机构：

[1] UCL, UCL Canc Inst, London WC1E 6BT, England

[2] UCL Med Sch, Dept Oncol, London, England

来源：

JOURNAL OF HEPATOLOGY | 2012年 / 56卷 / 03期

关键词：

Resistance; Chemotherapy; mTOR; Hypoxia; Hepatocellular; Doxorubicin; Sorafenib; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; METRONOMIC ORAL CYCLOPHOSPHAMIDE; BEVACIZUMAB PLUS CAPECITABINE; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER; COMBINATION CHEMOTHERAPY; SYSTEMIC TREATMENT; OXALIPLATIN GEMOX; 1ST-LINE THERAPY;

D O I：

10.1016/j.jhep.2011.07.031

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatocellular cancer is a significant global health problem yet the prognosis for the majority of patients has not changed significantly over the past few decades. For patients with advanced disease, sorafenib is currently the standard of care providing a survival advantage of 2-3 months in selected patients. Cytotoxic chemotherapy has been used for over 30 years but definite evidence that it prolongs survival has been lacking. Resistance remains a significant barrier for both targeted and cytotoxic agents and an understanding of the underlying mechanisms is critical if outcomes are to be improved. Here, we summarise the past and current data that constitute the evidence base for chemotherapy in HCC, review the causes of chemoresistance and suggest strategies to overcome these barriers. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

收藏

页码：686 / 695

页数：10

相关论文

共 75 条

[1] Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial [J].

Abou-Alfa, Ghassan K. ;

Johnson, Philip ;

Knox, Jennifer J. ;

Capanu, Marinela ;

Davidenko, Irina ;

Lacava, Juan ;

Leung, Thomas ;

Gansukh, Bolorsukh ;

Saltz, Leonard B. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19) :2154-2160

[2] GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells [J].

Andrieux, Lise O. ;

Fautrel, Alain ;

Bessard, Anne ;

Guillouzo, Andre ;

Baffet, Georges ;

Langouet, Sophie .

CANCER RESEARCH, 2007, 67 (05) :2114-2123

[3]

[Anonymous], J CLIN ONCOL

[4] Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma - Results of a multicenter phase 2 study [J].

Asnacios, Amani ;

Fartoux, Laetitia ;

Romano, Olivier ;

Tesmoingt, Chloe ;

Louafi, Samy S. ;

Mansoubakht, Touraj ;

Artru, Pascal ;

Poynard, Thierry ;

Rosmorduc, Olivier ;

Hebbar, Mohamed ;

Taieb, Julien .

CANCER, 2008, 112 (12) :2733-2739

[5] Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma [J].

Barbare, JC ;

Bouché, O ;

Bonnetain, F ;

Raoul, JL ;

Rongier, P ;

Abergel, A ;

Boige, V ;

Denis, B ;

Blanchi, A ;

Pariente, A ;

Milan, C ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4338-4346

[6] The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].

Beuvink, I ;

Boulay, A ;

Fumagalli, S ;

Zilbermann, F ;

Ruetz, S ;

O'Reilly, T ;

Natt, F ;

Hall, J ;

Lane, HA ;

Thomas, G .

CELL, 2005, 120 (06) :747-759

[7] Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial [J].

Boige, V. ;

Raoul, J-L ;

Pignon, J-P ;

Bouche, O. ;

Blanc, J-F ;

Dahan, L. ;

Jouve, J-L ;

Dupouy, N. ;

Ducreux, M. .

BRITISH JOURNAL OF CANCER, 2007, 97 (07) :862-867

[8] Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients [J].

Bottini, Alberto ;

Generali, Daniele ;

Brizzi, Maria Pia ;

Fox, Stephen B. ;

Bersiga, Alessandro ;

Bonardi, Simone ;

Allevi, Giovanni ;

Aguggini, Sergio ;

Bodini, Giuliana ;

Milani, Manuela ;

Dionisio, Rossana ;

Bernardi, Claudio ;

Montruccoli, Arianna ;

Bruzzi, Paolo ;

Harris, Adrian L. ;

Dogliotti, Luigi ;

Berruti, Alfredo .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3623-3628

[9] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Cavallo, Giovanna ;

Reni, Michele ;

Franceschi, Enrico ;

Bonaldi, Laura ;

Bertorelle, Roberta ;

Gardiman, Marina ;

Ghimenton, Claudio ;

Iuzzolino, Paolo ;

Pession, Annalisa ;

Blatt, Valeria ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4746-4753

[10] SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].

BRESSAC, B ;

KEW, M ;

WANDS, J ;

OZTURK, M .

NATURE, 1991, 350 (6317) :429-431

← 1 2 3 4 5 6 7 8 →